Health Management and Economics Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.
Department of Pharmacoeconomics and Pharmaceutical Management, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Trop Med Int Health. 2018 Dec;23(12):1326-1331. doi: 10.1111/tmi.13157. Epub 2018 Oct 24.
Pharmaceutical pricing is an important and contentious issue in middle- and low-income countries. The present study evaluated a value-based pricing system for estimating the price of interferon-beta (IFN-β).
Prices were estimated through the Willingness to Pay (WTP) system using the Discrete Choice Experiment (DCE) from the viewpoint of MS patients, levels of attributes and patients' willingness to pay for these attributes.
The results indicate that the new approach to pricing medicines leads to more integrated prices than the current system. The current prices of four brands were higher than their pharmaceutical market price; the prices of other brands were consistent with it.
Application of the proposed pricing system will help pharmaceutical companies make realistic price estimates of their products while accounting for patient preferences, which may enhance patients' adherence to treatment.
药品定价是中低收入国家的一个重要且有争议的问题。本研究评估了一种基于价值的定价系统，用于估算干扰素-β（IFN-β）的价格。
通过意愿支付（WTP）系统，使用离散选择实验（DCE）从 MS 患者的角度评估价格，包括属性水平和患者对这些属性的支付意愿。
结果表明，新的药品定价方法比现行系统产生了更综合的价格。四种品牌的现行价格高于其药品市场价格；其他品牌的价格与其一致。
应用建议的定价系统将帮助制药公司在考虑患者偏好的同时对其产品进行现实的价格估算，这可能会提高患者对治疗的依从性。
